SCHEMBL16615817

SCHEMBL16615817

O=C(O)c1c[nH]c(=O)c(C(F)(F)F)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ KHK P50053 1/20 0.37
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ ASPH Q12797 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ PABPC1 P11940 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ DYRK1A Q13627 1/20 0.33
▸ ALOX15 P16050 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ ACMSD Q8TDX5 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ DAO P14920 1/20 0.32
▸ HPGD P15428 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16598067 0.98 KDM4E (0.36) KDM4EALDH1A1KHKMEN1KMT2A
SCHEMBL21617985 0.76 KDM4E (0.39) KDM4EALDH1A1MEN1KMT2AASPH
SCHEMBL22439859 0.72 KDM4E (0.42) KDM4EALDH1A1DYRK1AALOX15TSHR
SCHEMBL16615908 0.68 HCAR2 (0.40) KDM4EMEN1KMT2ADYRK1AALOX15
SCHEMBL15167516 0.67 GFER (0.44) KDM4EPOLB
SCHEMBL22234858 0.67 KDM4E (0.43) KDM4EALDH1A1MEN1KMT2AASPH
SCHEMBL27087492 0.67 KDM4E (0.44) KDM4EMEN1KMT2AASPHMAPT
Hydrochloric Acid SCHEMBL16598199 0.67 HCAR2 (0.39) KDM4EMEN1KMT2ADYRK1AALOX15
SCHEMBL20582681 0.66 — —
SCHEMBL163471 0.66 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171447-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF MERCK SHARP & DOHME LLC (US) 2025-05-29 — — US disclosed
EP-4479056-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF Merck Sharp & Dohme LLC (US) 2024-12-25 — — EP disclosed
WO-2023158626-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-24 — — WO disclosed
WO-2023158626-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-24 — — WO disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 — — US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 — — US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 — — US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171447-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF ADORA2A, ADORA2B, ADORA1 KDM4E 3489/4885ALDH1A1 483/4885KHK 1974/4885
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 KDM4E 2241/4885ALDH1A1 3274/4885KHK 4630/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 KDM4E 2241/4885ALDH1A1 3274/4885KHK 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback